Anti–interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes☆

Gastrointestinal Eosinophilia

“…CCR3 antagonists), or humanized anti-IL-5 therapeutics are likely to be useful therapy in the future. Indeed, early clinical trials have supported their potential utility [60] . Gastrointestinal Eosinophilia…”

“…Currently, anti-IL-5 and antiIgE trials are in progress and some studies have shown promising results. [60] In severe cases refractory or dependent upon glucocorticoid therapy, intravenous alimentation or immunosuppressive antimetabolite therapy (azathioprine or 6-mercaptopurine) are alternatives. Finally, even if GERD is not present, neutralization of gastric acidity (with proton pump inhibitors) may improve symptoms and the degree of esophageal and gastric pathology.…”

Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels

“…18,20 Subject characteristics-Of the 25 subjects enrolled, 18 were diagnosed with a diverse set of HESs, as defined by a recent workshop (Table I). 22 Six subjects were diagnosed with EE.…”

“…Preliminary data in patients with HES and EE treated with anti-IL-5 have revealed promising results, including improvements in clinical parameters and levels of tissue eosinophilia. [17][18][19][20] The first randomized, double-blind, placebo-controlled trial of patients with HES was recently conducted and aimed at demonstrating the ability of anti-IL-5 to decrease prednisone dependence in HES not associated with the constitutively activated tyrosine kinase FIP1L1-platelet-derived growth factor receptor α (FIP1L1-PDGFRA). 21 Impressively, this international trial revealed a striking ability of anti-IL-5 to decrease prednisone doses, decrease blood eosinophilia, and maintain clinical stability compared with placebo.…”

DW2008S and its major constituents from Justicia procumbens exert anti‐asthmatic effect via multitargeting activity

“…This results in the release of various substances, such as histamine, leukotriene and prostaglandin D 2 , through degranulation of mast cells, causing mucus production and bronchoconstriction 3, 4, 5, 6. Thus, many studies have developed antibodies for the treatment or prevention of allergic asthma by targeting Th2 immune pathophysiological factors 7, 8, 9, 10. However, the clinical efficacies of these drugs are limited to alleviation of the condition.…”